Literature DB >> 21129328

The physiology of glucagon.

Gerald J Taborsky1.   

Abstract

This short review outlines the physiology of glucagon in vivo, with an emphasis on its neural control, the author's area of interest. Glucagon is secreted from alpha cells, which are a minority of the pancreatic islet. Anatomically, they are down stream from the majority islet beta cells. Beta-cell secretory products restrain glucagon secretion. Activation of the autonomic nerves, which innervate the islet, increases glucagon secretion. Glucagon is secreted into the portal vein and thus has its major physiologic action at the liver to break down glycogen. Glucagon thereby maintains hepatic glucose production during fasting and increases hepatic glucose production during stress, including the clinically important stress of hypoglycemia. Three different mechanisms proposed to stimulate glucagon secreted during hypoglycemia are discussed: (1) a stimulatory effect of low glucose directly on the alpha cell, (2) withdrawal of an inhibitory effect of adjacent beta cells, and (3) a stimulatory effect of autonomic activation. In type 1 diabetes (T1DM), increased glucagon secretion contributes to the elevated ketones and acidosis present in diabetic ketoacidosis (DKA). It also contributes to the hyperglycemia seen with or without DKA. The glucagon response to insulin-induced hypoglycemia is impaired soon after the development of T1DM. The mediators of this impairment include loss of beta cells and loss of sympathetic nerves from the autoimmune diabetic islet.
© 2010 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21129328      PMCID: PMC3005043          DOI: 10.1177/193229681000400607

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  71 in total

1.  Insulin regulation of lipolysis in nondiabetic and IDDM subjects.

Authors:  M D Jensen; M Caruso; V Heiling; J M Miles
Journal:  Diabetes       Date:  1989-12       Impact factor: 9.461

Review 2.  Endocrine regulation of protein breakdown in skeletal muscle.

Authors:  I C Kettelhut; S S Wing; A L Goldberg
Journal:  Diabetes Metab Rev       Date:  1988-12

3.  Role for autonomic nervous system to increase pancreatic glucagon secretion during marked insulin-induced hypoglycemia in dogs.

Authors:  P J Havel; R C Veith; B E Dunning; G J Taborsky
Journal:  Diabetes       Date:  1991-09       Impact factor: 9.461

4.  Intra-islet insulin permits glucose to directly suppress pancreatic A cell function.

Authors:  C J Greenbaum; P J Havel; G J Taborsky; L J Klaff
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

5.  Loss of potentiating effect of hypoglycemia on the glucagon response to hyperaminoacidemia in IDDM.

Authors:  S Caprio; W V Tamborlane; K Zych; K Gerow; R S Sherwin
Journal:  Diabetes       Date:  1993-04       Impact factor: 9.461

6.  A quantitative analysis of the sensory and sympathetic innervation of the mouse pancreas.

Authors:  T H Lindsay; K G Halvorson; C M Peters; J R Ghilardi; M A Kuskowski; G Y Wong; P W Mantyh
Journal:  Neuroscience       Date:  2006-01-04       Impact factor: 3.590

7.  Corticotrophin-releasing factor receptors within the ventromedial hypothalamus regulate hypoglycemia-induced hormonal counterregulation.

Authors:  Rory J McCrimmon; Zhentao Song; Haiying Cheng; Ewan C McNay; Catherine Weikart-Yeckel; Xiaoning Fan; Vanessa H Routh; Robert S Sherwin
Journal:  J Clin Invest       Date:  2006-06       Impact factor: 14.808

8.  Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release.

Authors:  Isobel Franklin; Jesper Gromada; Asllan Gjinovci; Sten Theander; Claes B Wollheim
Journal:  Diabetes       Date:  2005-06       Impact factor: 9.461

9.  Role of brain in counterregulation of insulin-induced hypoglycemia in dogs.

Authors:  D W Biggers; S R Myers; D Neal; R Stinson; N B Cooper; J B Jaspan; P E Williams; A D Cherrington; R T Frizzell
Journal:  Diabetes       Date:  1989-01       Impact factor: 9.461

10.  Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans.

Authors:  S R Heller; P E Cryer
Journal:  Diabetes       Date:  1991-02       Impact factor: 9.461

View more
  25 in total

1.  Pharmacokinetics modeling of exogenous glucagon in type 1 diabetes mellitus patients.

Authors:  Dayu Lv; Marc D Breton; Leon S Farhy
Journal:  Diabetes Technol Ther       Date:  2013-08-26       Impact factor: 6.118

Review 2.  Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis.

Authors:  Charlotte X Dong; Patricia L Brubaker
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-10-02       Impact factor: 46.802

Review 3.  Ketogenic Diet: an Endocrinologist Perspective.

Authors:  Aravind Reddy Kuchkuntla; Meera Shah; Saketh Velapati; Victoria M Gershuni; Tamim Rajjo; Sanjeev Nanda; Ryan T Hurt; Manpreet S Mundi
Journal:  Curr Nutr Rep       Date:  2019-12

Review 4.  Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes.

Authors:  Vikash Dadlani; Jordan E Pinsker; Eyal Dassau; Yogish C Kudva
Journal:  Curr Diab Rep       Date:  2018-08-29       Impact factor: 4.810

Review 5.  Safe glycemic management during closed-loop treatment of type 1 diabetes: the role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia.

Authors:  W Kenneth Ward; Jessica R Castle; Joseph El Youssef
Journal:  J Diabetes Sci Technol       Date:  2011-11-01

6.  Cross Talk Between Insulin and Glucagon Receptor Signaling in the Hepatocyte.

Authors:  Kirk M Habegger
Journal:  Diabetes       Date:  2022-09-01       Impact factor: 9.337

Review 7.  Central Mechanisms of Glucose Sensing and Counterregulation in Defense of Hypoglycemia.

Authors:  Sarah Stanley; Amir Moheet; Elizabeth R Seaquist
Journal:  Endocr Rev       Date:  2019-06-01       Impact factor: 19.871

8.  Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver-alpha-cell axis.

Authors:  Katrine D Galsgaard; Marie Winther-Sørensen; Cathrine Ørskov; Hannelouise Kissow; Steen S Poulsen; Hendrik Vilstrup; Cornelia Prehn; Jerzy Adamski; Sara L Jepsen; Bolette Hartmann; Jenna Hunt; Maureen J Charron; Jens Pedersen; Nicolai J Wewer Albrechtsen; Jens J Holst
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-10-03       Impact factor: 4.310

9.  Glucagon's Metabolic Action in Health and Disease.

Authors:  Anja Zeigerer; Revathi Sekar; Maximilian Kleinert; Shelly Nason; Kirk M Habegger; Timo D Müller
Journal:  Compr Physiol       Date:  2021-04-01       Impact factor: 9.090

Review 10.  Glucose Metabolism in Burns-What Happens?

Authors:  Silviu Constantin Badoiu; Daniela Miricescu; Iulia-Ioana Stanescu-Spinu; Alexandra Ripszky Totan; Silvia Elena Badoiu; Michel Costagliola; Maria Greabu
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.